Lupus nephritis is one of the most serious complications of systemic lupus erythematosus (SLE). It occurs when the immune system mistakenly attacks the kidneys, leading to inflammation and possibly to ...

The long-anticipated results of the Aspreva Lupus Management Study (ALMS) have finally been published. 1 The purpose of ALMS was to demonstrate the superiority of mycophenolate mofetil (MMF) over ...

In this recording from our virtual webinar on the American College of Rheumatology’s new Lupus Nephritis Treatment Guidelines, learn more about evidence-based, expert recommendations for adults and ...

A minimum of 3 years of sustained clinical remission may protect against an increase in disease activity and the development ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Brad Rovin, MD ...

The FDA has agreed to review an application from Roche that seeks approval in the U.S. of obinutuzumab as a treatment for ...

Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral treatment for active nephritis in patients with the autoimmune disease systemic lupus ...

– Gazyva is the only anti-CD20 monoclonal antibody in a randomized Phase III study to demonstrate a complete renal response benefit – – The filing application is based on data from the Phase ...